Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.83
- Piotroski Score 2.00
- Grade Buy
- Symbol (MCRB)
- Company Seres Therapeutics, Inc.
- Price $0.77
- Changes Percentage (5.66%)
- Change $0.04
- Day Low $0.72
- Day High $0.78
- Year High $2.05
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $1.25
- High Stock Price Target $1.25
- Low Stock Price Target $1.25
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.59
- Trailing P/E Ratio -1.04
- Forward P/E Ratio -1.04
- P/E Growth -1.04
- Net Income $-113,724,000
Income Statement
Quarterly
Annual
Latest News of MCRB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
To learn more about expanding C 155 into additional patient populations like auto HSCT and cancer neutropenia, refer to the full earnings call transcript. C 155's mechanism applies to both allo and au...
By Yahoo! Finance | 1 week ago -
Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years
Despite a recent 125% increase in Seres Therapeutics stock, long-term holders have faced an 84% decline over three years. With revenue growth but no profits, investors should be cautious. Diversificat...
By Yahoo! Finance | 4 months ago
